-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source | Metz medical scientists have proven in the past ten years that small organoids cultured from stem cells in the laboratory can be integrated into many organs, including mouse liver, lungs and other tissues for repair Damage to organs.
Recently, the top international academic journal Science magazine published a research paper titled: Cholangiocyte organoids can repair bile ducts after transplantation in the human liver.
The study proved that "mini bile ducts" cultured by adult bile duct cells can be transplanted into human livers.
This provides a new method for the treatment of liver disease, and also pave the way for the repair of donated organs so that more organs can be used for transplantation.
In patients with bile duct injury, such as those suffering from primary sclerosing cholangitis, the bile duct tends to become inflamed, forming scar tissue, narrowing and hardening the bile duct, causing bile to accumulate, and ultimately leading to liver tissue destruction.
Bile duct disease is an important culprit in 70% of children and 33% of adult liver transplants.
Researchers from the Cambridge Stem Cell Institute in the United Kingdom discovered in 2017 that cells extracted from human bile duct cells can be transplanted into mice to create structures similar to bile ducts.
In this new study this year, they tried to use this organoid to repair human organs.
Researchers generated different organoids from donated human bile duct cells from different parts of the human bile duct: intrahepatic bile duct, which is exposed to the lowest concentration of bile; common bile duct, which has an intermediate bile concentration; and gallbladder, which stores concentrated bile.
Then they used single-cell sequencing to check gene expression.
The higher the exposure of cells to bile acids in bile, the higher the expression of genes encoding proteins that protect them from degradation.
When the research team exposed the bile duct cells to bile acids, the cells increased the expression of protective genes.
This happens no matter where the cells originally came from in the liver, indicating that their gene expression is flexible and largely driven by the environment.
To prove this flexibility, the research team then transplanted these organoids into mice with chemically damaged bile ducts.
The results show that no matter where the donor cells are transplanted into the bile duct, they can fuse with host cells, regenerate damaged tissues, and produce appropriate proteins.
The mice that received the organ-like transplant survived, while the control animals that did not receive the organ-like transplant died quickly, indicating that the bile duct cells had a healing effect.
Experiments in mice showed that cholangioid cells can save cholangiopathies after transplantation.
Then, the research team cultivated a new set of human organs and transplanted them into three donated human livers (these organs are maintained in an in vitro artificial system).
Survive).
The researchers used these livers because routine evaluation before transplantation showed that these organs were not healthy enough to be donated to patients.
Similarly, the test results found that in the human liver, the transplanted organoids repaired damaged ducts and restored their functions.
Cholangiocytic cells were transplanted into the liver of people receiving NMP.
Therefore, this study confirmed that cell-based therapy can be used to repair damaged liver.
This is a huge advancement in bile duct cell biology and regenerative medicine.
In view of the chronic shortage of donor organs, it is important to find ways to repair damaged organs and even provide alternative methods for organ transplantation.
Organoids, as miniature and simplified versions of organs cultured in vitro, will undoubtedly accelerate the clinical treatment of various organs and diseases.
Organoids may be derived from one or several cells in the tissue, embryonic stem cells or induced pluripotent stem cells.
Since the beginning of 2010, this cultivation and transplantation technology has rapidly improved, and was named by The Scientist as one of the biggest scientific advances in 2013.
Scientists have learned how to create a suitable environment for cells so that they can form organoid structures in accordance with genetic instructions.
There may be as many types of organoids as there are different tissues and organs in the body.
So far, scientists have been able to produce organs similar to the brain, kidneys, tongue, lungs, intestines, stomach and liver.
In short, organoid technology has brought great hope for regenerative medicine.
At present, there is an urgent need to increase the supply of organs or provide alternative methods for whole organ transplantation in many clinical diseases.
There is always a shortage of organ donors worldwide, and only a limited number of patients can benefit from this treatment.
And cell-based therapy can provide an advantageous alternative.
However, the development of these new therapies is often hindered and delayed due to the lack of appropriate models to test their safety and effectiveness in humans, and more clinical trials are needed to verify them in the future.
Link to the paper: https://science.
sciencemag.
org/content/371/6531/839
Recently, the top international academic journal Science magazine published a research paper titled: Cholangiocyte organoids can repair bile ducts after transplantation in the human liver.
The study proved that "mini bile ducts" cultured by adult bile duct cells can be transplanted into human livers.
This provides a new method for the treatment of liver disease, and also pave the way for the repair of donated organs so that more organs can be used for transplantation.
In patients with bile duct injury, such as those suffering from primary sclerosing cholangitis, the bile duct tends to become inflamed, forming scar tissue, narrowing and hardening the bile duct, causing bile to accumulate, and ultimately leading to liver tissue destruction.
Bile duct disease is an important culprit in 70% of children and 33% of adult liver transplants.
Researchers from the Cambridge Stem Cell Institute in the United Kingdom discovered in 2017 that cells extracted from human bile duct cells can be transplanted into mice to create structures similar to bile ducts.
In this new study this year, they tried to use this organoid to repair human organs.
Researchers generated different organoids from donated human bile duct cells from different parts of the human bile duct: intrahepatic bile duct, which is exposed to the lowest concentration of bile; common bile duct, which has an intermediate bile concentration; and gallbladder, which stores concentrated bile.
Then they used single-cell sequencing to check gene expression.
The higher the exposure of cells to bile acids in bile, the higher the expression of genes encoding proteins that protect them from degradation.
When the research team exposed the bile duct cells to bile acids, the cells increased the expression of protective genes.
This happens no matter where the cells originally came from in the liver, indicating that their gene expression is flexible and largely driven by the environment.
To prove this flexibility, the research team then transplanted these organoids into mice with chemically damaged bile ducts.
The results show that no matter where the donor cells are transplanted into the bile duct, they can fuse with host cells, regenerate damaged tissues, and produce appropriate proteins.
The mice that received the organ-like transplant survived, while the control animals that did not receive the organ-like transplant died quickly, indicating that the bile duct cells had a healing effect.
Experiments in mice showed that cholangioid cells can save cholangiopathies after transplantation.
Then, the research team cultivated a new set of human organs and transplanted them into three donated human livers (these organs are maintained in an in vitro artificial system).
Survive).
The researchers used these livers because routine evaluation before transplantation showed that these organs were not healthy enough to be donated to patients.
Similarly, the test results found that in the human liver, the transplanted organoids repaired damaged ducts and restored their functions.
Cholangiocytic cells were transplanted into the liver of people receiving NMP.
Therefore, this study confirmed that cell-based therapy can be used to repair damaged liver.
This is a huge advancement in bile duct cell biology and regenerative medicine.
In view of the chronic shortage of donor organs, it is important to find ways to repair damaged organs and even provide alternative methods for organ transplantation.
Organoids, as miniature and simplified versions of organs cultured in vitro, will undoubtedly accelerate the clinical treatment of various organs and diseases.
Organoids may be derived from one or several cells in the tissue, embryonic stem cells or induced pluripotent stem cells.
Since the beginning of 2010, this cultivation and transplantation technology has rapidly improved, and was named by The Scientist as one of the biggest scientific advances in 2013.
Scientists have learned how to create a suitable environment for cells so that they can form organoid structures in accordance with genetic instructions.
There may be as many types of organoids as there are different tissues and organs in the body.
So far, scientists have been able to produce organs similar to the brain, kidneys, tongue, lungs, intestines, stomach and liver.
In short, organoid technology has brought great hope for regenerative medicine.
At present, there is an urgent need to increase the supply of organs or provide alternative methods for whole organ transplantation in many clinical diseases.
There is always a shortage of organ donors worldwide, and only a limited number of patients can benefit from this treatment.
And cell-based therapy can provide an advantageous alternative.
However, the development of these new therapies is often hindered and delayed due to the lack of appropriate models to test their safety and effectiveness in humans, and more clinical trials are needed to verify them in the future.
Link to the paper: https://science.
sciencemag.
org/content/371/6531/839
